Prevalent Metformin Use in Adults With Diabetes and the Incidence of Long COVID: An EHR-Based Cohort Study From the RECOVER Program

Steve Johnson; Sajjad Abedian; Til Stürmer‎; Jared D. Huling; Colby Lewis; John B. Buse; Shari B. Brosnahan; Praveen C. Mudumbi; Kristine M. Erlandson; Grace A. McComsey; Jonathan Arnold; Talia D. Wiggen; Rachel Wong; Shawn N. Murphy; Clifford J. Rosen; Rainu Kaushal; Mark G. Weiner; Carolyn T. Bramante

doi:10.2337/dca24-0032

Abstract

Studies show metformin use before and during SARS-CoV-2 infection reduces severe COVID-19 and postacute sequelae of SARS-CoV-2 (PASC) in adults. Our objective was to describe the incidence of PASC and possible associations with prevalent metformin use in adults with type 2 diabetes mellitus (T2DM).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Johnson et al. (2024) studied this question.

synapsesocial.com/papers/68e58323b6db643587520299 https://doi.org/10.2337/dca24-0032

View Full Paper

Ask AI

Bookmark

Share

Prevalent Metformin Use in Adults With Diabetes and the Incidence of Long COVID: An EHR-Based Cohort Study From the RECOVER Program

Abstract

Discussion

Cite This Study

Prevalent Metformin Use in Adults With Diabetes and the Incidence of Long COVID: An EHR-Based Cohort Study From the RECOVER Program

Abstract

Discussion

Cite This Study

Keep reading

Keep reading